Momentum is growing for Remplir™ in nerve-sparing prostate cancer surgery, with around 100 surgeries now performed using the flagship nerve repair device.
Orthocell Appoints Second Canadian Distributor for Remplirâ„¢
Orthocell has appointed its second distributor in Canada. The appointment completes national coverage across the US$75 million Canadian market, ensuring access for patients and healthcare providers nationwide.
First Remplirâ„¢ Surgical Case Completed in Hong Kong
Orthocell has announced the successful completion of the first Remplirâ„¢ surgical case in Hong Kong and the official launch of their flagship nerve repair medical device at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress.
Professor Minghao Zheng elected Fellow of the Australian Academy of Health and Medical Sciences Â
Professor Minghao Zheng, Orthocell’s Co-Founder and Chief Scientific Officer, has been elected as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).
Orthocell Appoints Exclusive Remplirâ„¢ Distributor for Hong Kong
Orthocell has appointed medical device distributor MontsMed as its exclusive in-country distributor for Remplir in the key Asian market of Hong Kong.Â
Orthocell secures global distribution rights to innovative bone regeneration technology
Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical – from 1.7% to 12.0% for a total consideration of AU$1.0 million – securing exclusive first right of refusal over global distribution rights their groundbreaking bone substitute product, PearlBoneâ„¢.
$30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio
Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.
Quarterly Report – period ended 30 September 2025
Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress.
Orthocell Announces Record Revenue of $3m for September Quarter
Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record revenue growth.
Orthocell Appoints First Distributor for Remplirâ„¢ in US$75m Canadian Market
Orthocell has appointed its first Canadian distributor for Remplirâ„¢, signalling the commencement of the Company’s commercial roll out in the US$75m Canadian nerve repair market.Â